Single administration of intracameral bimatoprost implant: IOP lowering, safety

Video
Conference|AAO

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

See more AAO coverage here

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
Related Content

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Gene Therapy: What’s to Come?

September 18th 2023

What to expect from virtual AAO 2020

November 5th 2020

Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400

September 15th 2023

What retina specialists want you to know about neovascular AMD and DME therapies: 10 top takeaways

September 15th 2023

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Gene Therapy: What’s to Come?

September 18th 2023

What to expect from virtual AAO 2020

November 5th 2020

Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400

September 15th 2023

What retina specialists want you to know about neovascular AMD and DME therapies: 10 top takeaways

September 15th 2023

Study: Researchers find new mechanisms that cause blindness, opening the door to future treatments

September 22nd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Gene Therapy: What’s to Come?

September 18th 2023

What to expect from virtual AAO 2020

November 5th 2020

Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400

September 15th 2023

What retina specialists want you to know about neovascular AMD and DME therapies: 10 top takeaways

September 15th 2023
© 2023 MJH Life Sciences

All rights reserved.